Skip to main content
main-content

Genitourinary cancers

Expert opinion

05-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Updated KEYNOTE-426 data

Elizabeth Plimack presents the 2-year update of the KEYNOTE-426 study pitting the combination of pembrolizumab plus axitinib against sunitinib for treatment-naïve advanced renal cell carcinoma (1:45).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

04-06-2020 | ASCO 2020 | Conference coverage | Video

Expert highlights: Genitourinary cancers at ASCO 2020

Axel Merseburger takes us through his picks of the genitourinary cancers track of the virtual 2020 ASCO Annual Meeting, including the JAVELIN Bladder 100 and KEYNOTE-426 trials (10:28).

04-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The KEYNOTE-146/Study 111 trial

Chung-Han Lee reports the final analysis of KEYNOTE-146/Study 111 trial of lenvatinib plus pembrolizumab in metastatic clear-cell renal cell carcinoma after immune checkpoint inhibitor therapy (4:57).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

03-06-2020 | ASCO 2020 | Conference coverage | Video

Expert comment: The JAVELIN Bladder 100 study

Elizabeth Plimack tells us why the avelumab switch maintenance strategy trialled in JAVELIN Bladder 100 could be a game changer for the field of advanced urothelial cancer (3:51).

01-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The JAVELIN Bladder 100 trial

Thomas Powles discusses the phase 3 trial investigating the use of maintenance avelumab after first-line chemotherapy in patients with advanced urothelial cancer (6:19).

01-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Initial data from CCC19

Jeremy Warner provides a comprehensive overview of the findings from the first 1018 patients with cancer and COVID-19 enrolled in the CCC19 registry (14:40).

01-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The FRACTION-RCC study

Toni Choueiri reports preliminary results from the FRACTION-RCC study showing encouraging efficacy of nivolumab plus ipilimumab in advanced renal cell carcinoma patients who have progressed on prior immunotherapy (3:11).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

31-05-2020 | ASCO 2020 | Conference coverage | Video

Expert comment: Antiandrogens in nonmetastatic CRPC

Tomasz Beer highlights the key messages and caveats of the overall survival data from the PROSPER, SPARTAN, and ARAMIS trials of enzalutamide, apalutamide, and darolutamide, respectively, in the nonmetastatic castration-resistant prostate cancer setting (10:25).

31-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The TheraP trial

Michael Hofman explains why the TheraP study of LuPSMA versus cabazitaxel in men with metastatic castration-resistant prostate cancer is even more relevant in light of the recently reported CARD trial (4:24).

29-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The SPARTAN OS data

Boris Hadaschik discusses the final overall survival analysis of the phase 3 placebo-controlled SPARTAN trial of apalutamide for nonmetastatic castration-resistant prostate cancer (6:00).

25-03-2020 | Genitourinary cancers | Podcast | Audio

Managing patients with genitourinary cancers in the time of COVID-19

Genitourinary oncologists Cora Sternberg and Axel Merseburger share their experience of managing cancer patients during the COVID-19 pandemic, comparing perspectives from a US and German stand point.

16-12-2019 | Renal cell carcinoma | Video | Article

Axel Merseburger: Recent developments in metastatic renal cell carcinoma

Axel Merseburger provides an overview of the most promising trials and biomarkers in renal cell carcinoma at ESMO 2019.

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA.

06-12-2019 | Bladder cancer | Feature | Article

A closer look at the NCCN patient guidelines for bladder cancer

Thomas Flaig discusses the NCCN patient-oriented guidelines for bladder cancer, with a view to explaining the need for the guidance and what patients can hope to get from it.

07-10-2019 | Prostate cancer | Video | Article

Expert comment: The STAMPEDE study

Eleni Efstathiou shares her views on the STAMPEDE analysis indicating that docetaxel may be an option for hormone-naïve prostate cancer regardless of metastatic disease burden (2:16).

07-10-2019 | Renal cell carcinoma | Video | Article

Researcher comment: A novel CXCR4 inhibitor for RCC and a novel immunotherapy endpoint

David McDermott talks through his renal cell carcinoma research exploring the use of a novel oral CXCR4 inhibitor and treatment-free survival as an alternative endpoint for immunotherapy trials (4:03).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

04-10-2019 | Renal cell carcinoma | Video | Article

Expert highlights: RCC immunotherapy at ESMO 2019

Axel Merseburger presents his round-up of the most interesting research on immunotherapy in renal cell carcinoma at the ESMO Congress 2019, including the TITAN RCC study and additional analyses from JAVELIN Renal 101 (3:14).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

04-10-2019 | Castration-resistant prostate cancer | Video | Article

Researcher comment: Cabazitaxel a new third-line option in mCRPC

Ronald de Wit tells us why the CARD trial results are likely to change the paradigm for the treatment of metastatic castration-resistant prostate cancer (3:58).

03-10-2019 | Castration-resistant prostate cancer | Video | Article

Researcher comment: PROfound improvement in outcomes with olaparib in mCRPC

The PROfound trial evaluated olaparib in metastatic castration-resistant prostate cancer ─ Maha Hussain discusses the clinical implications and practical applications of the findings (2:40).

02-10-2019 | Castration-resistant prostate cancer | Video | Article

Expert comment: The CARD trial

Silke Gillessen comments on the phase IV CARD study investigating third-line cabazitaxel in men with metastatic castration-resistant prostate cancer (3:02). 

02-10-2019 | Castration-resistant prostate cancer | Video | Article

Expert comment: The PROfound trial

Eleni Efstathiou explains why the PROfound trial of the PARP inhibitor olaparib is the first step towards treating metastatic castration-resistant prostate cancer in a more precise way (3:09).

Image Credits